Ziprasidone: From pharmacology to the clinical practice. One year of experience

Actas Espanolas de Psiquiatria

Volumn 33, Issue 5, 2005, Pages 311-324

  Baca, E ^a   Azanza, J R ^b   Giner, J ^c   Saiz, J ^d   Vallejo, J ^e   Diez T ^f   Madrigal, M ^f  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f PFIZER INC   (United States)

Author keywords

Doses; Schizophrenia; Tolerability; Ziprasidone

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; SEROTONIN RECEPTOR; THIAZOLE DERIVATIVE; ZIPRASIDONE;

ARTICLE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; DRUG TOLERANCE; HUMAN; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; HUMANS; PIPERAZINES; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, MUSCARINIC; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; THIAZOLES;

EID: 24344482412     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Bagnall AM, Lewis RA, Leitner ML Ziprasidone for schizophrenia and severe mental illness (Cochrane review). The Cochrane Library, Issue 1. Oxford: Update software, 2004.
2. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-3.
3. Seeman P, Lee T, Chau Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;717-9.
4. Peroutka SJ. Snyder relationship of neuroleptic drug effects at brain dopamine, serotonine, alpha adrenergic and histamine receptors to clinical potency. Am J Psychiatry 1980;137:1518-22.
5. Farde L, Wiesel FA, Halldin C, Hogeberg T, Nilson L, Sjogren I, et al. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988;45:71-6.
6. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedwall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-44.
7. Meltzer H, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Progr Neuropsychopharmacology 2003;27:1159-72.
8. Ceulemans DL, Gelders YG, Hoppenbrouwers ML, Reyntjens AJ, Janssen PA. Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology (Berl) 1985;85(3):329-32.
9. Wadenberg ML, Hicks PB, Richter JT, Young KA. Enhancement of antipsychotic like properties of raclopride in rats using the selective serotonin2A receptor antagonist MDL 100,907. Biol Psychiatry 1998;44:508-15.
10. Sawaguchi T, Goldman-Rakic PS: D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 1991;251:947-50.
11. Ichiwaka J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 2002;26:325-39.
12. Gunasekara NS. Ziprasidone. A review of its use in schizophrenia and schizoaffective disorder. Drug 2002;62:1217-51.
13. Zorn SH, Bebel LA, Schmidt AW. Pharmacological and neurochetnical studies with the new antipsychotic ziprasidone. En: Palomo T, Beninger R, Archer T, editores. Interactive monoaminergic basis of brain disorders. Vol 4. Dopamine Disease States. Madrid, Sintesis, 1998; p. 377-94.
14. Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, et al. PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004;161:818-25A.
15. Bench CJ, Lammertsma AA, Dolan RJ, Grasby PM, Warrington SJ, Gunn K, et al. Dose dependent occupancy of central dopamine receptors by novel neuroleptic CP-88, 059-01: a study using positron emission tomography and 11C-raclopride. Psychopharmacology 1993;112:308-14.
16. Bench CJ, Lammertsma AA, Grasby PM, Dolan RJ, Warrington SJ, Boyce M, et al. The time course of binding to striatal dopamine receptors by the neuroleptic ziprasidone determined by positron emission tomography. Psychopharmacology 1996;124:141-7.
17. Fischman AJ, Bonab AA, Babich JW, Alpert NM, Rauch SL, Elmaleh DR, et al. Positron emission tomographic analysis of central 5-hydroxitryptamine 2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J Pharmacol Exp Ther 1996;279:939-47.
18. Miceli JJ, Wilner KD, Hansen RA, Johnson AC, Apseloff G, Gerber N. Single and multiple-dose pharmacocinetics of ziprasidone under non fasting conditions in healthy male volunteers: Br J Clin Pharmacol 2000;49(Suppl. 1):5S-13S.
19. Xiberas X, Martinot JL, Mallet L Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotics drugs in patients with schizophrenia. Br J Psychiatry 2001;179:503-8.
20. Corripio I, Catafau AM, Pérez-Sola V, Puigdemont D, Pascual JC, Mena E, et al. Ziprasidone versus haloperidol differences in striatal D2 receptor occupancy: a 123i-IBZM study in schizophrenia exacerbation. Prog Neuro-psychopharmacology 2004 [in press].
21. Kapur S, Zipursky RB, Remington G, Joles C, Dasilva J, Wilson AA, et al. 5HT2 y D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998;155:921-28.
22. Schmidt A, Lebel LA, Howard HR, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001;425:197-201.
23. Bymaster FP, Katner JS, Nelson DL Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002;27:699-711.
24. Stahl S, Shayegan DK. The Psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003;64(Suppl. 19):6-12.
25. Cudennec A, Fage D, Bénavides J, Scatton B. Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat. Brain Res 1997;768:257-65.
26. Weiden P, Iqbal N, Mendelowitz A, Tandon R, Ximbroff D, Ross R. La mejor práctica clínica con ziprasidona: actualización tras un año de experiencia. J Psychiatr Pract 2002;8:2.
27. Rollema H, Lu Y, Schmidt AW, et al. 5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 2000;48:229-37.
28. Sumiyoshi T, Jayathilake K, Meltzer HY. The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia. Schizophr Res 2003;59:7-16.
29. Ichikawa J, Ishii H, Bonaccorso S. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001;76:1521-31.
30. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT1A) receptors. J Pharmacol Exp Ther 2000;295:853-61.
31. Tatsumi M, Jansen K, Blakely RD. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999;368:277-83.
32. Daniel DG, Zimbroff DL, Potkin SG. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999;20:491-505.
33. Kane JM. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials. J Clin Psychiatry 2003;64(Suppl. 19):19-25.
34. Keck P Jr, Buffenstein A, Ferguson J. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 1998;140:173-84.
35. Arató M, O'Connor R, Meltzer HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002;17:207-15.
36. th Annual Meeting of the American Psychiatric Association. May 17-22, 2003. San Francisco (California).
37. Arango López C, Brenlla González J, Chamorro García L, Sarramea Crespo F, Gastó Ferrer C, Gómez Beneyto M y Grupo de Investigadores del estudio ZIS. Estudio ZIS: efectividad y tolerabilidad de ziprasidona oral en pacientes con esquizofrenia. VIII Congreso Nacional de Psiquiatría; 20-23 October 2004. Bilbao (Spain).
38. Sarramea Crespo F, Chamorro García L, Brenlla González J, Arango López C, Gastó Ferrer C, Gómez Beneyto M y Grupo de Investigadores del estudio ZIS. Actitud del paciente hacia la medicación en pacientes tratados con ziprasidona oral. VIII Congreso Nacional de Psiquiatría; 20-23 October 2004. Bilbao (Spain).
39. Goff DC, Posever T, Herz L. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998;18:296-304.
40. Hirsch SR, Kissling W, Bäuml J. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002;63:516-23.
41. Khanna S, Kane J, Rajadhyaksha S. Ziprasidone vs chlorpromazine in treatment-refractory schizophrenia [poster]. Presented at the International Congress on Schizophrenia Research (ICOSR). March 29-April 2, 2003. Colorado Springs, Colorado.
42. Simpson GM. A double-blind multicenter comparison of the safety and efficacy of ziprasidone versus olanzapine in inpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 2004;161:1837-55.
43. th Annual Meeting of the American Psychiatric Association. May 5-10, 2001. New Orleans (USA).
44. th Annual Meeting of the American Psychiatric Association. May 5-10, 2001. New Orleans (USA).
45. st Annual Meeting of the American College of Neuropsychopharmacology ACNP 2002. San Juan (Puerto Rico).
46. Addington D, Pantelis C, Dineen M, Benattia I, Romano S. Efficacy and tolerability of ziprasidone vs risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry 2004;65:1624-33.
47. Addington D, Pantelis C, Benattia I. Ziprasidone vs risperidone in schizophrenia: an 8-week, double-blind trial. Eur Neuropsychopharmacol 2002;12(Suppl. 3)S314.
48. th Annual Meeting of the American Psychiatric Association. May 17-22, 2003. San Francisco (USA).
49. Olie JP, Spina E, Benattia I. Ziprasidone vs amisulpride for negative symptoms of schizophrenia. Eur Neuropsychopharmacol 2002;12(Suppl. 3).
50. McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr Res 2000;45:175-84.
51. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia, are we measuring the right stuff? Schizophr Bull 2000;261:119-6.
52. Harvey P, Meltzer H, Simpson GM, Potkin S, Loebel A, Siu C, Romano SJ. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 2004;66:101-13.
53. Harvey P, Siu CO, Romano S. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology 2004;172:324-32.
54. th Institute on Psychiatric Services, Boston, November, 2003.
55. Harvey P. Ziprasidone and the cognition: the evolving story. J Clin Psychiatry 2003;64(Suppl. 19):33-9.
56. Loebel A, Siu C, Romano S. Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr 2004;9:357-64.
57. Tandon R, Harrigan E, Zorn S. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutical potential. J Serotonin Res 1997;4:159-77.
58. US package insert risperidone. http://www.fda.gov/cder/foi/label/2003/ 20272s-26,27,20588s-17,18,21444s-2,3_risperdal_lbl.pdf. Visited el 22/9/04.
59. US package insert olanzapine. In: http://www.fda.gov/cder/foi/label/2004/ 20592se1-019_zyprexa_lbl.pdf. Visited 22/11/04.
60. US package insert quetiapine. In: http://www.fda.gov/cder/foi/label/2004/ 20639s020lbl.pdf. Visited 22/11/04.
61. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity from the US. Food and Drug Administration (FDA) Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004;27:596-601.
62. Monografía de Zeldox, 2003. Madrid: Pfizer, 2003
63. Harrigan E, Miceli J, Anziano R, Watsky E, Reeves K, Cutler N, et al. A randomised evaluation of the effects of six antipsychotic agents on QTc in the absence and presence of metabolic inhibition. J Clin Pharmacol 2004;24:62-9.
64. th Institute on Psychiatric Services. Boston, 2003.
65. th Annual Meeting of the American Psychiatric Association. May 1-6 2004. New York (USA).